Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
about
Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
description
im September 2018 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2018
@uk
name
Lenalidomide combined with low ...... tory multiple myeloma patients
@en
Lenalidomide combined with low ...... tory multiple myeloma patients
@nl
type
label
Lenalidomide combined with low ...... tory multiple myeloma patients
@en
Lenalidomide combined with low ...... tory multiple myeloma patients
@nl
prefLabel
Lenalidomide combined with low ...... tory multiple myeloma patients
@en
Lenalidomide combined with low ...... tory multiple myeloma patients
@nl
P2093
P2860
P356
P1433
P1476
Lenalidomide combined with low ...... tory multiple myeloma patients
@en
P2093
Aart Beeker
Andries C Bloem
Anjan Thakurta
Annemiek Broijl
Berris van Kessel
Chad C Bjorklund
Ellen van der Spek
Gerard M J Bos
Harry R Koene
Henk M Lokhorst
P2860
P304
34009-34021
P356
10.18632/ONCOTARGET.26131
P407
P577
2018-09-21T00:00:00Z